DACOGEN

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.

Contact Details: Bloomington Minnesota 55437 United States of America Tel: Fax: Email: techsupport@dacogen.com. WWW: www.dacogen.com/

Loading...

BioNews Results for DACOGEN:
FDA Sends Warning Letters for Dacogen and Fosrenol	Drugs.com:  Nov 18 2009 3:44AM Matching: dacogen
FDA Warns Eisai About Dacogen Promotional Material	FDA News:  Nov 17 2009 4:25AM Matching: dacogen
FDA Sends Warning Letters for Dacogen and Fosrenol	Pharma Live:  Nov 16 2009 1:08PM Matching: dacogen
Warning Letters 2009	U.S. Food and Drug Administration:  Nov 14 2009 2:40AM Matching: dacogen
SuperGen-Glaxo Deal Couldn't Have Come at a Better Time	Seeking Alpha:  Oct 27 2009 11:16PM Matching: dacogen
Promote your company here: BioNewsCast - Press Release Distribution	→View more DACOGEN news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 276 times since April 2007, the link to the organisation's website has been followed 69 times

Recent Search Terms used to find this page: 2000 2001 2002 2003 2004 2005 2006 2007 | .

Search for more companies in Bloomington

Search for more companies in Minnesota

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for DACOGEN